A vaccine developed by Modern Biotechnology with the United States National Institutes of Health (NIH) generated a “Robust” immune response by stopping the replication of the new coronavirus in monkey lungs and nose, according to results released Tuesday.
This is one of the two western vaccines, along with the one developed by the University of Oxford with the Australian pharmacist AstraZeneca, which began to be experienced on a large scale.
For its part, the United States invested almost US $ 1 billion to support the investigations, although the same nation paid almost twice as much to the Pfizer and Biontech laboratories to ensure 100 million doses.
Seven out of eight monkeys vaccinated in this study, and exposed four weeks later to the new coronavirus, had not recorded a detectable replication of the pathogen in their lungs. two days later, and none had viruses in their noses according to the results published in the New England Journal of Medicine.
Scientists found that the administration in two doses 28 days apart Not only did it generate antibodies against the coronavirus, but it also produced T lymphocytes, which are essential for the immune response.
“It is the first time that an experimental primate-covid-19 vaccine has shown its ability to produce a rapid viral control in the airways superiors, ”the NIH said in a statement.
Scientists noted that the vaccine developed by Oxford had no effect in the amount of virus in the monkeys nose.
Reducing viruses in the lungs would make the disease less aggressive while decreasing those in the nose would reduce the potential contagion from those around the infected person.
But only human trials, which are in progress, will make it possible to verify whether one or the other vaccine protects people.
For the Oxford / AstraZeneca vaccine, the results could be known from September and from October in the case of the Moderna vaccine.
–
